| |
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
Today’s Big NewsJan 25, 2024 |
| By James Waldron In a move that will be seized on as a sign that the IPO window is reopening in 2023, CG Oncology has not only become the first biotech to go public this year but overshot its own estimates. |
|
|
|
By Gabrielle Masson Saudi Arabia has launched a national biotech strategy in efforts to become an international biotech hub within the next 16 years. |
By James Waldron Kronos Bio had already trimmed back its headcount and pipeline in the wake of a mid-stage cancer flop. Now, it’s the company’s C-suite who are heading to the exits. |
Sponsored by Cardinal Health Cell and gene therapy patients often require support throughout their treatment journey. Learn key considerations for developing patient support programs. |
By Max Bayer Third Rock is fortifying its ranks, hiring three new venture partners and promoting two others at the firm. Among the new hires is Karuna Therapeutics founder Steve Paul. |
By Nick Paul Taylor Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that match its target product profiles (TPPs). |
By Nick Paul Taylor Glenmark Pharmaceuticals has entered (PDF) the subcutaneous checkpoint inhibitor space, agreeing to pay "low double digit millions" for the chance to launch envafolimab in markets including India. |
By Angus Liu Three months after launching an investigation into the risk of secondary T-cell cancers after treatment with a CAR-T medicine, the FDA has shared more information on the cases that it has seen. But questions remained unanswered. |
By Andrea Park Last year's increase easily outstripped not only the “high single-digit” rate Abbott had predicted at the start of the year, but also the 7% growth rate it had posted in the two years leading up to 2020. |
By Fraiser Kansteiner Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing trend by charting what it called an “exceptional" performance. And the company sees more growth ahead. |
By Andrea Park The single-port system, dubbed da Vinci SP, has racked up clearances in the U.S. in recent years allowing it to be used in urology and transoral otolaryngology procedures. The newly bestowed CE mark allows European surgeons to use the SP platform in an even wider range of surgeries. |
By Kevin Dunleavy Two months ago, in presenting quarterly earnings, CEO Barry Greene said Sage Therapeutics was on its way to becoming a “leaner and stronger company.” Part of that mission will come to fruition later this year with a move of its headquarters in Cambridge, Massachusetts. Sage will shift from its 103,000-square-foot headquarters to a 30,567-square-foot office three blocks away, the company said in a regulatory filing. |
By Anastassia Gliadkovskaya The U.S. healthcare sector is responsible for about 8.5% of greenhouse gas emissions, largely from hospital care and from physician and clinical services. More than half of clinicians said their organization’s climate policies and actions affected their decision to remain in their current job. |
Fierce podcastsDon’t miss an episode |
| At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
